Propanc Biopharma Inc Dossier
Qualitative Analysis
Business overview
Propanc Biopharma, Inc. (Nasdaq: PPCB) is a development-stage biopharmaceutical company focused on developing novel treatments for chronic diseases, specifically targeting recurrent and metastatic solid tumors. The company's scientific platform is based on the therapeutic use of pancreatic proenzymes to target and eradicate cancer stem cells. Its lead product candidate, PRP, is a fixed-dose combination of the pancreatic proenzymes trypsinogen and chymotrypsinogen administered via weekly intravenous injection. Propanc is also developing Rec-PRP, a fully synthetic recombinant version of its lead therapy. The company operates with a minimal internal footprint, relying on research collaborations and contract development organizations to advance its pipeline.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing lead therapeutic candidate PRP (a fixed-dose combination of trypsinogen and chymotrypsinogen) toward a Phase 1b First-In-Human clinical study in 30-40 patients with advanced solid tumors at the Peter MacCallum Cancer Centre in Melbourne, Australia.
Expected impact: Transitioning the company from a pre-clinical to a clinical-stage biopharmaceutical entity, targeting the $3B+ pancreatic cancer market.
Developing Rec-PRP, a fully synthetic recombinant version of PRP designed for improved stability, global scalability, and large-scale production.
Expected impact: Provides a backup clinical compound with enhanced commercial scalability and intellectual property protection.
Planning to establish a digital asset treasury to diversify company assets and create long-term value for shareholders.
Expected impact: Diversification of corporate assets and alignment with modern corporate treasury trends.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Engaged for the GMP production of PRP finished drug product. The partnership includes pre-production in August 2026, an engineering run in October 2026, and GMP manufacturing starting in December 2026 to support the Phase 1b clinical trial.
Terms: Not explicitly disclosed.
Executed in March 2026 to establish and validate a liquid chromatography-mass spectrometry (LC-MS) based pharmacokinetics (PK) assay to measure PRP and its active enzyme forms in human serum during the Phase 1b study.
Terms: Not explicitly disclosed.
A multi-year collaboration focused on evaluating a senescence-modulating (anti-aging) compound to mitigate cell aging and support patent applications for proenzymes in cancer and age-related chronic diseases like fibrosis.
Terms: Multi-year research agreement; specific financial terms not disclosed.